Kiess W, Greenstein L A, White R M, Lee L, Rechler M M, Nissley S P
Metabolism Branch, National Cancer Institute, Bethesda, MD 20892.
Proc Natl Acad Sci U S A. 1987 Nov;84(21):7720-4. doi: 10.1073/pnas.84.21.7720.
We previously identified in fetal rat serum a component capable of specifically binding radiolabeled insulin-like growth factor type II (IGF-II) that is considerably larger than both the fetal (40 kDa) and the adult (150 kDa) carrier proteins. We now present immunologic and affinity crosslinking data to show that this binding species is the type II IGF receptor. Rat serum was gel-filtered on a Sephadex G-200 column (0.05 M NH4HCO3, pH 8), and 125I-labeled IGF-II (125I-IGF-II) binding was measured in individual column fractions. 125I-IGF-II binding activity was found in the void volume of the column in addition to the carrier protein regions. Competitive binding studies using 125I-IGF-II and binding activity from the Sephadex G-200 void volume showed the characteristics of the type II receptor: IGF-II was more potent than IGF-I, and insulin did not compete. Moreover, a specific anti-type II IGF receptor antibody (no. 3637) completely blocked 125I-IGF-II binding. 125I-IGF-I did not bind to the void volume pool, demonstrating the absence of the type I IGF receptor in rat serum. Affinity crosslinking of 125I-IGF-II to the Sephadex G-200 void volume material demonstrated a specific band at 210 kDa without reduction and at 240 kDa after reduction of disulfide bonds. The serum type II IGF receptor size was confirmed by immunoblotting the void volume material with antiserum 3637, which revealed a band slightly smaller (approximately 10 kDa) than the type II IGF receptor from rat placental membranes. Immunoquantitation by immunoblotting using pure type II IGF receptor from rat placental membranes as standard showed a developmental pattern. In fetal rat serum (19-days gestation) and in sera from 3-, 10-, and 20-day-old rats, the concentrations of receptor protein were similar (1-5 micrograms/ml). The level of the type II IGF receptor in serum declined dramatically between age 20 and 40 days, but the receptor was still measurable at age 12 mo. We conclude that the type II IGF receptor is present in rat serum and is developmentally regulated.
我们先前在胎鼠血清中鉴定出一种成分,它能够特异性结合放射性标记的II型胰岛素样生长因子(IGF-II),其分子量远大于胎儿型(40 kDa)和成年型(150 kDa)载体蛋白。我们现在提供免疫和亲和交联数据,以表明这种结合物质是II型IGF受体。将大鼠血清在Sephadex G-200柱(0.05 M NH4HCO3,pH 8)上进行凝胶过滤,并在各个柱级分中测量125I标记的IGF-II(125I-IGF-II)结合情况。除了载体蛋白区域外,在柱的空体积中也发现了125I-IGF-II结合活性。使用125I-IGF-II和来自Sephadex G-200空体积的结合活性进行的竞争性结合研究显示出II型受体的特征:IGF-II比IGF-I更有效,胰岛素不参与竞争。此外,一种特异性抗II型IGF受体抗体(编号3637)完全阻断了125I-IGF-II的结合。125I-IGF-I不与空体积池结合,表明大鼠血清中不存在I型IGF受体。125I-IGF-II与Sephadex G-200空体积物质的亲和交联显示,在不还原时出现一条210 kDa的特异性条带,在二硫键还原后出现一条240 kDa的条带。通过用抗血清3637对空体积物质进行免疫印迹,证实了血清II型IGF受体的大小,该条带比大鼠胎盘膜中的II型IGF受体略小(约10 kDa)。以大鼠胎盘膜中的纯II型IGF受体为标准,通过免疫印迹进行免疫定量显示出一种发育模式。在胎鼠血清(妊娠19天)以及3日龄、10日龄和20日龄大鼠的血清中,受体蛋白的浓度相似(1 - 5微克/毫升)。血清中II型IGF受体的水平在20至40日龄之间急剧下降,但在12月龄时仍可检测到。我们得出结论,II型IGF受体存在于大鼠血清中,并且受到发育调控。